KR20190031314A - 로티고틴 베헤네이트, 그 제조 방법 및 그 용도 - Google Patents

로티고틴 베헤네이트, 그 제조 방법 및 그 용도 Download PDF

Info

Publication number
KR20190031314A
KR20190031314A KR1020197005257A KR20197005257A KR20190031314A KR 20190031314 A KR20190031314 A KR 20190031314A KR 1020197005257 A KR1020197005257 A KR 1020197005257A KR 20197005257 A KR20197005257 A KR 20197005257A KR 20190031314 A KR20190031314 A KR 20190031314A
Authority
KR
South Korea
Prior art keywords
rotigotine
behenate
rotigotine behenate
degrees
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020197005257A
Other languages
English (en)
Korean (ko)
Inventor
미나 양
용타오 지앙
잉 멩
타오 왕
치안치안 쑤
씬 샤오
천제 샤
Original Assignee
산동 루예 파마슈티칼 컴파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산동 루예 파마슈티칼 컴파니 리미티드 filed Critical 산동 루예 파마슈티칼 컴파니 리미티드
Publication of KR20190031314A publication Critical patent/KR20190031314A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
KR1020197005257A 2016-07-21 2016-07-21 로티고틴 베헤네이트, 그 제조 방법 및 그 용도 Abandoned KR20190031314A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/090803 WO2018014277A1 (zh) 2016-07-21 2016-07-21 罗替戈汀山嵛酸酯及其制备方法和用途

Publications (1)

Publication Number Publication Date
KR20190031314A true KR20190031314A (ko) 2019-03-25

Family

ID=60992805

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197005257A Abandoned KR20190031314A (ko) 2016-07-21 2016-07-21 로티고틴 베헤네이트, 그 제조 방법 및 그 용도

Country Status (15)

Country Link
US (2) US10669249B2 (https=)
EP (1) EP3489227B1 (https=)
JP (1) JP6751208B2 (https=)
KR (1) KR20190031314A (https=)
CN (1) CN109415335B (https=)
AU (1) AU2016415408B2 (https=)
BR (1) BR112019001035A2 (https=)
CA (1) CA3030043C (https=)
ES (1) ES2855976T3 (https=)
MY (1) MY195897A (https=)
PH (1) PH12018550212A1 (https=)
PL (1) PL3489227T3 (https=)
RU (1) RU2717542C9 (https=)
SG (1) SG11201811543XA (https=)
WO (1) WO2018014277A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение
CN108341798B (zh) * 2017-01-23 2021-05-25 沈阳药科大学 罗替戈汀衍生物及其制备和应用
CN114423746A (zh) * 2019-09-30 2022-04-29 山东绿叶制药有限公司 化合物及其制备方法和用途
JP7621009B2 (ja) * 2020-10-27 2025-01-24 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 テトラヒドロナフタレン系化合物、その医薬組成物及びその使用
WO2024208226A1 (zh) * 2023-04-04 2024-10-10 广州市恒诺康医药科技有限公司 四氢萘类化合物、其药物组合物及其用途
CN119504742B (zh) * 2024-11-18 2025-10-28 陕西师范大学 一种娃儿藤碱和安托芬的全合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
KR101481643B1 (ko) 2010-11-25 2015-01-12 산동 루예 파마슈티칼 컴파니 리미티드 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물
WO2013168033A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9956201B2 (en) * 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение

Also Published As

Publication number Publication date
BR112019001035A2 (pt) 2019-04-30
PL3489227T3 (pl) 2021-05-04
JP2019523297A (ja) 2019-08-22
MY195897A (en) 2023-02-27
US20200255396A1 (en) 2020-08-13
RU2717542C1 (ru) 2020-03-24
PH12018550212A1 (en) 2019-10-28
AU2016415408B2 (en) 2019-04-11
EP3489227B1 (en) 2020-10-21
US10669249B2 (en) 2020-06-02
CN109415335A (zh) 2019-03-01
AU2016415408A1 (en) 2019-01-17
CA3030043C (en) 2021-01-19
JP6751208B2 (ja) 2020-09-02
SG11201811543XA (en) 2019-02-27
WO2018014277A1 (zh) 2018-01-25
CN109415335B (zh) 2020-06-05
US20190330177A1 (en) 2019-10-31
EP3489227A4 (en) 2020-01-22
ES2855976T3 (es) 2021-09-27
EP3489227A1 (en) 2019-05-29
US11111227B2 (en) 2021-09-07
RU2717542C9 (ru) 2020-08-12
CA3030043A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
KR20190031314A (ko) 로티고틴 베헤네이트, 그 제조 방법 및 그 용도
JP7153030B6 (ja) オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法
TWI572594B (zh) 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之結晶型及其製備方法
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
CN103145617B (zh) 菲啶类衍生物及其药物组合物和其制备方法与应用
JP2019523297A5 (https=)
JP2012509351A (ja) 有機化合物のフッ素化
CN113880770A (zh) 依托咪酯衍生物及其中间体、制备方法和用途
KR20250143329A (ko) 갑상선 호르몬 유사체의 전구약물, 이의 제조 방법 및 사용 방법
CN108727347B (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
TWI745764B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
HK40004499A (en) Rotigotine behenate, and manufacturing method and application thereof
HK40004499B (en) Rotigotine behenate, and manufacturing method and application thereof
CN104650109A (zh) 紫杉烷类化合物
JP6533794B2 (ja) タキサン化合物、その調製方法およびその使用
CN107540589A (zh) 一种艾尔骨化醇晶型、药物组合物及制备方法和应用
TWI717859B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
DE102020121965A1 (de) Neuartige Derivate des Psilocins mit Prodrug-Eigenschaften
AU2011307952A1 (en) Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods for preparing the same and use of the same
RU2779119C2 (ru) Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения
HK40108373A (zh) Aurora a选择性抑制剂的多晶型及其用途
WO2020012248A1 (en) Novel naphthylenyl compounds for long-acting injectable compositions and related methods
WO2018008737A1 (ja) ジヒドロキシ化合物又はその塩、及びパーキンソン病治療薬又は予防薬

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20190221

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201125

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210513

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee